News

Shares of Savara (NASDAQ: SVRA) rose more than 9% Tuesday morning after the company released first-quarter earnings. The stock is up more than 38% so far this year. Savara is a a clinical-stage phar

Investing in the cannabis industry is tricky. Some investors may be tempted to entirely shun the space based on its performance over the last two years. However, a few companies still offer

Shares of Horizon Therapeutics (NASDAQ: HZNP), a rare disease specialist, were down by 17.4% on heavy volume as of 10:14 a.m. ET Tuesday morning. The drugmaker's shares are falling after news broke

Investing in high-yield dividend stocks for income is one thing, but getting a high yield at a great valuation can be a formula for long-term success when it comes to investing. In this video, we

Image source: The Motley Fool.

CorMedix (NASDAQ: CRMD)Q1 2023 Earnings CallMay 15, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Shares of Sarepta Therapeutics (NASDAQ: SRPT) were skyrocketing 24.9% higher as of 10:37 a.m. ET on Monday. The huge gain came after the company announced Friday evening that a U.S. Food and Drug

On May 9, Novavax (NASDAQ: NVAX) shareholders got a much-needed reprieve from the stock's downward trajectory over the last year. Its shares popped by around 40%, leaving it up 12% in the last 30

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The World Health

Raise your hand if you've heard that telecom giant AT&T (NYSE: T) stock has been cheap before. Shares have been getting cheaper for years -- Ma Bell's stock price is down 40% over the past decade.

Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a

Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark. And smaller companies that lack any approved

The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. But history has demonstrated time and again that a buy-and-hold strategy is one of the best

Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race. To make matters worse, earlier this year, Novavax even questioned its ability

Shares of Cassava Sciences (NASDAQ: SAVA) were up 18.7% for the week, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech stock closed at $22.32 last week, then

Biogen (NASDAQ: BIIB) has been a polarizing stock to own over the past few years. Aduhelm's accelerated approval sent the stock soaring a few years ago, but after controversy surrounding its

Image source: The Motley Fool.

Geron (NASDAQ: GERN)Q1 2023 Earnings CallMay 11, 2023, 10:30 a.m. ET

Operator

Continue reading

Source Fool.com

Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq

Shares of the rare disease juggernaut Sarepta Therapeutics (NASDAQ: SRPT) fell by 12.6% through the first three and a half days of trading this week, according to data provided by S&P Global Market